Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that marketed and emerging biologic agents will be the greatest drivers of sales growth in the rheumatoid arthritis market through 2013.

According to the new Pharmacor study entitled Rheumatoid Arthritis, the launch and subsequent uptake of novel agents will fuel additional rheumatoid arthritis sales growth and will impact the market dynamics of the three leading biologic agents currently used to treat the disease: Amgen/Wyeth/Takeda's Enbrel, Centocor (a Johnson & Johnson subsidiary)/Schering-Plough's Remicade, and Abbott/Eisai's Humira.

The study also finds that U.S. Medicare reform legislation, approved in November 2003 and going into effect in 2006, will have a significant impact on the market dynamics of biologic agents in the United States, where use and sales of biologics are the greatest.

"Only Remicade, which must be administered intravenously by a trained medical professional, is currently reimbursed by Medicare," said Daphne Monie, analyst at Decision Resources. "However, Medicare reform legislation slated to go into effect in 2006 will allow for the reimbursement of self-administered injectable drugs, such as Enbrel and Humira, encouraging growth in the use of more convenient self-administered TNF-alpha inhibitors in the United States."

Rheumatoid Arthritis Drug Market in Europe and Japan to Grow Dramatically The European rheumatoid arthritis drug market will experience the most significant growth of any major market in the next ten years. Patient share attributable to biologic agents and total sales in this region will increase dramatically as more-aggressive treatment paradigms are adopted. These paradigms include earlier use of biologics, the accumulation of long-term safety data, and the emergence of newer, less expensive agents in cost- conscious Europe.

The Japanese rheumatoid arthritis drug market will undergo dramatic growth in the next ten years, fueled predominantly by the launch and subsequent uptake of additional biologic agents in Japan. Remicade is the only biologic currently available in this region, but Enbrel was recently approved with a launch expected in 2005. Additionally, Chugai/Roche's Actemra and Humira are expected to launch in Japan within ten years.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563,
emarshall@dresources.com

Mass Exodus From HMOs in the Pacific Northwest is Slowing While PPO Growth is Moderating

View Now